Cargando…

Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide

To date there are 9 known diseases caused by an expanded polyglutamine repeat, with the most prevalent being Huntington's disease. Huntington's disease is a progressive autosomal dominant neurodegenerative disorder for which currently no therapy is available. It is caused by a CAG repeat e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evers, Melvin M., Pepers, Barry A., van Deutekom, Judith C. T., Mulders, Susan A. M., den Dunnen, Johan T., Aartsma-Rus, Annemieke, van Ommen, Gert-Jan B., van Roon-Mom, Willeke M. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164722/ https://www.ncbi.nlm.nih.gov/pubmed/21909428 http://dx.doi.org/10.1371/journal.pone.0024308

Ejemplares similares

Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain
por: Zalachoras, Ioannis, et al.
Publicado: (2011)

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
por: Synofzik, Matthis, et al.
Publicado: (2022)

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007)

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
por: Toonen, Lodewijk J.A., et al.
Publicado: (2017)

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Cost-effective HRMA pre-sequence typing of clone libraries; application to phage display selection
por: Pepers, Barry A, et al.
Publicado: (2009)

Antisense Oligonucleotide-Induced Amyloid Precursor Protein Splicing Modulation as a Therapeutic Approach for Dutch-Type Cerebral Amyloid Angiopathy
por: Daoutsali, Elena, et al.
Publicado: (2021)

Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP)
por: Yılmaz-Eliş, A Seda, et al.
Publicado: (2013)

Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3
por: Toonen, Lodewijk J. A., et al.
Publicado: (2016)

Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease
por: van Roon-Mom, Willeke MC, et al.
Publicado: (2008)

Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
por: Veltrop, Marcel, et al.
Publicado: (2018)

Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor
por: Kemaladewi, Dwi U, et al.
Publicado: (2014)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Antisense-mediated isoform switching of steroid receptor coactivator-1 in the central nucleus of the amygdala of the mouse brain
por: Zalachoras, Ioannis, et al.
Publicado: (2013)

Selection and characterization of llama single domain antibodies against N-terminal huntingtin
por: Schut, Menno H., et al.
Publicado: (2014)

The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice
por: Verhaart, Ingrid E C, et al.
Publicado: (2014)

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
por: Goyenvalle, Aurélie, et al.
Publicado: (2023)

Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA
por: Mastrokolias, Anastasios, et al.
Publicado: (2012)

Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain
por: Toonen, Lodewijk J.A., et al.
Publicado: (2018)

Effect of post-mortem delay on N-terminal huntingtin protein fragments in human control and Huntington disease brain lysates
por: Schut, Menno H., et al.
Publicado: (2017)

Nonclinical Exon Skipping Studies with 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results
por: van Putten, Maaike, et al.
Publicado: (2019)

Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012)

Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies
por: Evers, Melvin M., et al.
Publicado: (2013)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
por: van Vliet, Laura, et al.
Publicado: (2008)

Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
por: Jirka, Silvana M G, et al.
Publicado: (2015)

Making (anti-) sense out of huntingtin levels in Huntington disease
por: Evers, Melvin M, et al.
Publicado: (2015)

Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide
por: Kourkouta, Eleni, et al.
Publicado: (2019)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
por: Goossens, Remko, et al.
Publicado: (2023)

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
por: van Deutekom, Judith, et al.
Publicado: (2023)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
por: van Putten, Maaike, et al.
Publicado: (2014)

Delivery is key: lessons learnt from developing splice‐switching antisense therapies
por: Godfrey, Caroline, et al.
Publicado: (2017)

Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy
por: Jirka, Silvana M.G., et al.
Publicado: (2018)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
por: Hammond, Suzan M, et al.
Publicado: (2021)

Therapeutic exon skipping for dysferlinopathies?
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2010)

Antisense-Oligonucleotide Mediated Exon Skipping in Activin-Receptor-Like Kinase 2: Inhibiting the Receptor That Is Overactive in Fibrodysplasia Ossificans Progressiva
por: Shi, SongTing, et al.
Publicado: (2013)

Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro
por: González-Barriga, Anchel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8l5hmslbub1m8betkva9lb460g